Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiochemotherapy with gemcitabine + oxaliplatin for unresectable locally advanced pancreatic cancer
2010-020379-22Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and oxaliplatin in pancreatic cancer (PC) (2 cohorts), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Safety of treatment and Proportion of resectable patients after radiochemotherapy. Started Sep 2010; status: active.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2010-020379-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020379-22.